Institute of Pharmacogenetics
- Prof. Dr. med. Winfried Siffert
Managing Director: | Prof. Dr. med. Winfried Siffert |
E-Mail: | |
Office: | Doris Siffert |
Phone: | +49 (0) 201-723-34 70 |
Fax: | +49 (0) 201-723-59 68 |
Homepage: |
Facts and Figures
Molecular genetic and pharmacogenetic examinations per year: 100
Focus areas
The Institute of Pharmacogenetics focuses on investigating genetic variants that have an impact on the response to drugs and other forms of medical treatment. These genetic variants may be located in transport proteins, in metabolic pathways, or in pharmacological targets. The Institute also conducts research on genetic modifications co-determining disease progression and treatment response. The main interest in this field is in cardiovascular disease and cancer. The Institutes director is licensed to conduct certain molecular genetic tests that are reimbursable under German Statutory Health Insurance regulations, and these tests are offered to patients paying for their own care as well. The most frequent tests are for toxicity associated with azathoprin, 5-FU, and irinotecan treatments. Cytochrome P450 variants are studied as well, as are tests for the diagnosis of thrombophilia and hemochromatosis.
Special consultations
Pharmacogenetic consultation by appointment
Fields of Research
- Development of genetic tests for use in tumor treatments
- Research on the role of genetic variants in cardiovascular disease
- Development of genetic tests for the prediction of drug effects and side effects
Number of patients
Approximately 100 per year
Staff
The Institute of Pharmacogenetics employs 3 physicians, 2 scientists, and 4 technicians.